



Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to  
 December 31, 2013.

---

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Section 1—Conflict Minerals Disclosure**

**Items 1.01 Conflict Minerals Disclosure and Report**

**Conflict Minerals Disclosure**

1

This Form SD, filed by Symmetry Medical Inc. (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period beginning January 1, 2013 and ending December 31, 2013.

A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.02 hereto and is publicly available through our website: [www.symmetrymedical.com](http://www.symmetrymedical.com) (under the “Investor Relations” section and “SEC Filings” subsection).

**Item 1.02 Exhibits**

The Company has filed, as an exhibit to this Form SD, the Conflict Minerals Report required by Item 1.01.

**Section 2.01—Exhibits**

The following exhibit is filed as part of this report

Exhibit 1.02—Conflict Minerals Report

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Symmetry Medical Inc.

By /s/ Fred L. Hite  
Fred L. Hite

June 2, 2014  
(Date)

Chief Financial Officer

---

**EXHIBIT INDEX**

**Symmetry Medical Inc.**

**Form SD**

<b>Exhibit No.</b>	<b>Description</b>
------------------------	--------------------

1.02	Conflict Minerals Report
------	--------------------------

2